Challenges in Developing a Validated Biomarker for Angiogenesis Inhibitors: The Motesanib Experience

نویسندگان

  • Michael B. Bass
  • Bin Yao
  • Yong-Jiang Hei
  • Yining Ye
  • Gerard J. Davis
  • Michael T. Davis
  • Barbara A. Kaesdorf
  • Sabrina S. Chan
  • Scott D. Patterson
  • Jose Luis Perez-Gracia
چکیده

[This corrects the article DOI: 10.1371/journal.pone.0108048.].

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Angiokinase inhibitors in non-small-cell lung cancer

2015 Angiogenesis is an essential component of tumor growth and metastasis. To date, an anti-VEGF antibody, bevacizumab, in combination with paclitaxel and carboplatin in the first-line setting is the only approved antiangiogenic treatment in non-small-cell lung cancer (NSCLC). Angiokinase inhibitors are oral small-molecule agents. They not only inhibit the VEGF pathway, but also target other i...

متن کامل

In vitro metabolism of the novel, highly selective oral angiogenesis inhibitor motesanib diphosphate in preclinical species and in humans.

Motesanib diphosphate is a novel, investigational, highly selective oral inhibitor of the receptor tyrosine kinases vascular endothelial growth factor receptors 1, 2, and 3, the platelet-derived growth factor receptor, and the stem cell factor receptor (Kit). The in vitro metabolic profiles of [(14)C]motesanib were examined by using microsomes and hepatocytes from preclinical species and humans...

متن کامل

Ab-Initio and Conformational Analysis of a Potent VEGFR-2 Inhibitor: A Case Study on Motesanib

Vascular endothelial growth factor receptor-2 (VEGFR-2); a cell surface receptor for vascular endothelial growth factors, is a key pharmacological target involved in the cell proliferation/angiogenesis. It has been revealed that VEGFR-2 induces proliferation through activation of the extracellular signal-regulated kinases pathway. In this regard, targeting the VEGFR-2 has been considered as an ...

متن کامل

Ab-Initio and Conformational Analysis of a Potent VEGFR-2 Inhibitor: A Case Study on Motesanib

Vascular endothelial growth factor receptor-2 (VEGFR-2); a cell surface receptor for vascular endothelial growth factors, is a key pharmacological target involved in the cell proliferation/angiogenesis. It has been revealed that VEGFR-2 induces proliferation through activation of the extracellular signal-regulated kinases pathway. In this regard, targeting the VEGFR-2 has been considered as an ...

متن کامل

Multikinase Inhibitor Motesanib Effects Alone and Combined with a Selective COX-2 Inhibitor in Colorectal Cancer Cells

Colorectal cancer (CRC) is a common solid tumor and it is a leading cause of cancer related death especially in developed countries (Center et al., 2009). About 500,000 deaths are reported per year worldwide due to CRC. Environmental factors, dietary habits, inflammatory bowel disease, age, male sex, and hereditary syndromes are a higher risk in the development of this disease (Chu, 2012). Impr...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 9  شماره 

صفحات  -

تاریخ انتشار 2014